PCAT1 and prostate cancer: Within lncRNA PCAT1, a significantly hypermethylated m6A peak enriched in exon 2 was shown in tumor tissues (Figure 5E) and has been reported to suppress castration-resistant prostate cancer progression by activating AKT and NF-κB signaling (24).